Text Size

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.

Wirta, D.L.; Kuwayama, Y.; Lu, F.; Shao, H.; Odani-Kawabata, N.


  • 2022
  • Journal of Ocular Pharmacology and Therapeutics
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Eye Research Foundation, Newport Beach, California, USA; Fukushima Eye Clinic, Osaka, Japan; Product Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA; Product Development Division (NOK), Santen Pharmaceutical Co., Ltd., Osaka, Japan

Related Publications

MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists

Sharif N.A.; Millar J.C.; Zode G.; Ota T.


Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: Two-Year Results from a Randomized, Multicenter Study

Panarelli J.F., Moster M.R., Garcia-Feijoo J., Flowers B.E., Baker N.D., Barnebey H.S., Grover D.S., Khatana A.K., Lee B., Nguyen T., Stiles M.C., Sadruddin O., Khaw P.T., Vold S., McFarland M., Stiles M., Stechschulte A., Strom A., Reynolds A., Noecker R., Thimons J., Khaimi M., Allen E., Sarkisian S., Barnebey H., Golez E., Feldman R., Bell N., Blieden L., Cantor L., WuDunn D., Catoira-Boyle Y., Chen H., Evans J., Martin E., Sozeri Y., Srivastava V., Wise R., Schwartz K., Grover D., Butler M., Emanuel M., Fellman R., Godfrey D., Smith O., Kornmann H., Khatana A., Hagee D., Kuhlman B., Zink J., Moster M., Dale E., Pro M., Baker D., Chambers M., Lehmann D., Caprioli J., Francis B., Giaconi J., Law S., Nouri-Mahdavi K., Coleman A., Flynn W., Rashid E., Reilly C., Rice R., Sidoti P., Panarelli J., Garg R., Tania Tai T.Y., Vinod K., Harizman N., Ritch R., Reiss G., Dewan V., Patel S., Sorenson C., Larsen C., Samuelson T., Hansen M., Barth T., Blakstad A., Buboltz M., Fahmy A., Fahmy M., Montealegre K., Mizener M., Whitted P., Lim M., Brandt J., Baik A., Jiang A., Brown S.V.L., Breunig A.C., Gorla M.S.R., Riss I., Feijoo G., Mendez Hernandez C., Martinez de la Casa J., Dupré Pelaez M., Fernandez Vidal A., García Sáenz S., Morales Fernandez L., Sáenz Francés F., Santos Bueso E., Perucho Gonzalez L., Beckers H.J.M., Kujovic S., Nardi M., Maglionico M.N., Nasini F., Passani A., Strouthidis N., Barton K., Clarke J., Gazzard G., Jayaram H., Khaw P., Papadopoulos M., Puertas R., Toth M., Lunt D., Triolo G., Kam R., Levine J., Flowers B., Nair U., Simmons S., Pokabla M., INN005 Study Group


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022